Development of a Well-Characterized Cynomolgus Macaque Model of Marburg Virus Disease for Support of Vaccine and Therapy Development.

Abstract

Marburg virus (MARV) is a filovirus that can infect humans and nonhuman primates (NHPs), causing severe disease and death. Of the filoviruses, Ebola virus (EBOV) has been the primary target for vaccine and therapeutic development. However, MARV has an average case fatality rate of approximately 50%, the infectious dose is low, and there are currently no approved vaccines or therapies targeted at infection with MARV. The purpose of this study was to characterize disease course in cynomolgus macaques intramuscularly exposed to MARV Angola variant. There were several biomarkers that reliably correlated with MARV-induced disease, including: viral load; elevated total clinical scores; temperature changes; elevated ALT, ALP, BA, TBIL, CRP and decreased ALB values; decreased lymphocytes and platelets; and prolonged PTT. A scheduled euthanasia component also provided the opportunity to study the earliest stages of the disease. This study provides evidence for the application of this model to evaluate potential vaccines and therapies against MARV and will be valuable in improving existing models.

• Authors: Kendra J Alfson, Yenny Goez-Gazi, Michal Gazi, Ying-Liang Chou, Nancy A Niemuth, Marc E Mattix, Hilary M Staples, Benjamin Klaffke, Gloria F Rodriguez, Carmen Bartley, Anysha Ticer, Elizabeth A Clemmons, John W Dutton 3rd, Anthony Griffiths, Gabe T Meister, Daniel C Sanford, Chris M Cirimotich, Ricardo Carrion Jr
• Journal: Vaccines (Vaccines (Basel)) Vol. 10 Issue 8 (Aug 14 2022) ISSN: 2076-393X [Print] Switzerland
• PMID: 36016203 (Publication Type: Journal Article)